Rap­port Ther­a­peu­tics sets out for $122M Nas­daq de­but as IPO back­log seeks fresh air

Clin­i­cal-stage neu­ro­science biotech Rap­port Ther­a­peu­tics will seek about $122 mil­lion in net pro­ceeds from its ini­tial pub­lic of­fer­ing, ac­cord­ing to new se­cu­ri­ties pa­per­work out­lin­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER